Spruce Biosciences, Inc. (SPRB) Investor Relations Documents

Spruce Biosciences, Inc. (SPRB) investor relations documents from the company's IR site: 1 presentation, 39 press releases; latest deck 2026-08-12. Read in-app with summaries. First-party data.

Corporate Presentation: Spruce Bio's TA-ERT for MPS IIIB shows durable normalization of CSF HS and stabilization of cognitive/motor skills, with BLA submission targeted for Q4 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-12PresentationCorporate Presentation
2026-08-12Press releaseSpruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-12Press releaseCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
2026-08-03Press releaseSpruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
2026-07-27Press releaseSpruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
2026-07-08Press releaseSpruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
2026-06-29Press releaseSpruce Biosciences Joins the Russell 3000® Index
2026-06-22Press releaseSpruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
2026-06-15Press releaseSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Co
2026-06-08Press releaseSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B
2026-05-28Press releaseSpruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
2026-05-27Press releaseSpruce Biosciences to Participate in Upcoming Conferences in June
Press releaseSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Press releaseSpruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
2026-03-02Press releaseSpruce Biosciences to Present at Upcoming Investor Conferences in March
2026-02-18Press releaseSpruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome
2026-02-17Press releaseSpruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026-02-05Press releaseLong-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s P
2026-01-28Press releaseSpruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
Press releaseSpruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Press releaseSpruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Press releaseSpruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
2024-11-11Press releaseSpruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
2024-08-12Press releaseSpruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
2024-05-13Press releaseSpruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
2024-03-13Press releaseSpruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
2023-11-13Press releaseSpruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
2023-08-14Press releaseSpruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
2023-05-15Press releaseSpruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates
2023-03-16Press releaseSpruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
2022-11-10Press releaseSpruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
2022-08-10Press releaseSpruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-05-11Press releaseSpruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-03-14Press releaseSpruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
2021-11-15Press releaseSpruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
2021-08-10Press releaseSpruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
2021-05-12Press releaseSpruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates
2021-03-22Press releaseSpruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates
2020-11-18Press releaseSpruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Press releaseSpruce Biosciences Announces Key Management and Board Appointments

SPRB overview · SPRB earnings · SPRB financials · SPRB KPIs · SPRB ownership · SPRB peers · SPRB filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.